NCT05022589

Brief Summary

The goal of this project is to further develop and evaluate a computerized cognitive-training program designed to extend older adults' functional independence and reduce accidental falls (i.e., reduce factors that contribute to fall risk; including cognitive abilities/executive functions). This intervention may benefit a large population of vulnerable older adults with elevated fall risk and lack of long-term viable treatment options.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
32

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Aug 2022

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 20, 2021

Completed
6 days until next milestone

First Posted

Study publicly available on registry

August 26, 2021

Completed
12 months until next milestone

Study Start

First participant enrolled

August 9, 2022

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 19, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 19, 2024

Completed
2.1 years until next milestone

Results Posted

Study results publicly available

June 10, 2026

Completed
Last Updated

June 10, 2026

Status Verified

June 1, 2026

Enrollment Period

1.7 years

First QC Date

August 20, 2021

Results QC Date

October 16, 2025

Last Update Submit

June 9, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Net Promoter Score (NPS)

    NPS (Net Promoter Score) is a whole number on a scale of -100 to +100, calculated by subtracting the percentage of Detractors from the percentage of Promoters. Promoters (score 9-10) are likely to exhibit value-creating behaviors, such as referring other potential program participants. Detractors (score 0-6) are less likely to do so. Passives (score 7-8) fall in between. Passives count toward the total number of respondents, which decreases the percentage of Promoters and Detractors and pushes the score toward 0. Higher score is better.

    At 10 weeks

Secondary Outcomes (12)

  • Program Adoption Rate

    10 weeks

  • Usability - Program Navigation - Platform is Accessible and Easy to Navigate

    10 weeks

  • Usability - Perceived Benefits - Felt Program Was Therapeutic

    10 weeks

  • Usability - Whether the Program Helped Participants Make a Positive Change in Their Activities of Daily Living

    10 weeks

  • Program Training Levels Completed

    10 weeks

  • +7 more secondary outcomes

Study Arms (1)

Experimental Treatment

EXPERIMENTAL

Computerized plasticity-based adaptive cognitive training requiring a total maximum of 50 treatment sessions, 5 sessions per week, \~30 minutes per session.

Other: Computerized Plasticity-Based Adaptive Cognitive Training

Interventions

Computerized plasticity-based adaptive cognitive training requiring a total maximum of 50 treatment sessions, 5 sessions per week, \~30 minutes per session.

Also known as: rSTAND
Experimental Treatment

Eligibility Criteria

Age65 Years+
Sexall
Healthy VolunteersNo
Age GroupsOlder Adult (65+)

You may qualify if:

  • Participants who are 65 years of age or older.
  • Participants must be US residents.
  • Participant with at least one self-reported fall within the last 1 year or difficulty walking one half a mile or difficulty climbing one flight of stairs.
  • Participants who are fluent English speakers from the age of 12, per self-report, to ensure reasonable neuropsychological results on key assessments.
  • Participant must have adequate sensorimotor capacity to perform the program, including visual capacity adequate to read from a computer screen at a normal viewing distance, auditory capacity adequate to understand normal speech, and motor capacity adequate to control a computer mouse or a tablet.

You may not qualify if:

  • Participants had joint replacement surgery or significant join/leg injury less than one year prior to the screening visit.
  • Participants have a joint replacement surgery scheduled within the next 6 months.
  • Participants use a walker or wheelchair on a regular basis.
  • Participants have a diagnosis of benign paroxysmal positional vertigo (BPPV), labyrinthitis or suffers migraines that result in chronic vertigo.
  • Participants self-reports vision or hearing difficulties that would interfere with the ability to complete the study tasks.
  • Participants with untreated psychiatric conditions, including substance abuse/dependence disorders, recent hospitalization, ongoing chemotherapy or other cancer treatment.
  • Participants with medical illnesses, injuries or conditions predisposing to imminent functional and/or cognitive decline (e.g. multiple sclerosis, stroke, traumatic brain injury, dementia, etc.)
  • Participants enrolled in a concurrent clinical trial involving an intervention targeting physical functioning to prevent falls; investigational pharmaceutical; nutraceutical; medical device; or behavioral treatment that could affect the outcome of this study. However, participation in standard treatments (e.g., occupational therapy) or use of prescribed medications (e.g., anti-depressants) is allowable.
  • Participants using computer-based cognitive training programs or has used it within a month of the consent date.
  • Participants who answered 'yes' to questions 4 (Active Suicidal Ideation with Intent) or 5 (Active Suicidal Ideation with Specific Plan and Intent) on the Columbia-Suicide Severity Rating Scale (C-SSRS) or 'yes' to any of the suicide-related behaviors (actual attempt, interrupted attempt, aborted attempt, preparatory act or behavior) on the C-SSRS "Suicidal Behavior" if the ideation or behavior occurred within 2 months from Participant's date of consent.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Posit Science Corporation

San Francisco, California, 94111, United States

Location

Results Point of Contact

Title
Dr. Tom Van Vleet
Organization
Posit Science Corporation

Study Officials

  • Thomas Van Vleet, PhD

    Posit Science Corporation

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 20, 2021

First Posted

August 26, 2021

Study Start

August 9, 2022

Primary Completion

April 19, 2024

Study Completion

April 19, 2024

Last Updated

June 10, 2026

Results First Posted

June 10, 2026

Record last verified: 2026-06

Locations